News
Driving Breakthroughs: Your Role in the 2024 NETRF Grant Cycle and Neuroendocrine Cancer Research
At NETRF, our dedication to advancing research is paramount because it holds the key to improving treatments and ultimately finding cures for neuroendocrine cancer. Research
New Clinical Trial Focuses on Use of Antibody-Drug Conjugate in Neuroendocrine Tumors and Carcinomas
A new first-in-human clinical trial at the National Institutes of Health in Bethesda, Maryland, is exploring the use of an antibody-drug conjugate (ADC), ADCT-701, in
Cabozantinib Evokes Response in Some Clinical Trial Participants with Metastatic Pheo/Para
The results of a phase 2 clinical trial, the Natalie Trial, suggest that the drug cabozantinib may hold promise as a therapeutic option for some
Lutathera® Approved by FDA as First Medication for Pediatric Patients with Certain NETs
The U.S. Food and Drug Administration approved Lutathera® as the first therapy specifically for patients 12 to 17 years of age who have somatostatin receptor-positive
Carrie Camino Joins NETRF’s Board of Directors
Carrie Camino joined the NETRF Board of Directors in April of 2024. Carrie is a retired business consultant and partner with West Monroe Partners, where
Advancing Neuroendocrine Tumor Research Through a New Clinically Relevant Mouse Model
One of the main challenges in neuroendocrine tumor (NET) research is the scarcity of models that accurately represent the disease. These models are essential for
Shared Multi-Omic Data for Advancing Neuroendocrine Neoplasm Research
NETRF-funded researchers have recently reported in the journal GigaScience the first multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms (NENs). This includes large cell
NETRF’s Commitment to Excellence in Research Funding
At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment
Retreatment Efficacy of 177Lu-DOTATATE: A U.S. Center’s Findings
Recent advancements have broadened the spectrum of treatments for advanced NETs, encompassing a range of therapies that include peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.
NETRF-funded Researchers Win Top Awards at ENETS
Four NETRF-funded researchers were recognized for excellence and received awards at the recent European Neuroendocrine Tumor Society (ENETS) annual meeting in Vienna, Austria. CEO Elyse